公开(公告)号：US11357798B2

公开(公告)日：2022-06-14

申请号：US15749766

申请日：2016-08-03

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kohji Nishida ,  Ryuuhei Hayashi ,  Yoichi Honma ,  Toru Okubo ,  Shun Shibata

IPC: A61K35/28 ,  A61P27/02 ,  C12N5/0775 ,  C12N5/00 ,  C12Q1/02 ,  A61K35/12

Abstract: The present invention relates to mesenchymal stem cell-derived microparticles having activity that promotes the growth of corneal epithelial stem cells and/or corneal epithelial cells, activity that maintains corneal epithelial stem cells in an undifferentiated state or promotes the formation of colonies thereby, and function that protects corneal epithelium.

公开(公告)号：US12291727B2

公开(公告)日：2025-05-06

申请号：US16981455

申请日：2019-03-28

Applicant: Osaka University

Inventor： Kohji Nishida ,  Ryuhei Hayashi ,  Toru Okubo ,  Yoichi Honma

IPC: C12N5/074 ,  A61K35/55

Abstract: Provided is a method for producing a stem cell-derived lacrimal gland tissue, the method comprising isolating SSEA4 and CD104 double positive cells from a self-formed ectodermal autonomous multi-zone (SEAM) cell population derived from pluripotent stem cells and three-dimensionally culturing the isolated cells in a medium with epidermal growth factor (EGF) and a ROCK inhibitor to produce a cell population expressing a lacrimal gland-related protein. The present invention provides a lacrimal gland organoid produced from pluripotent stem cells including iPS cells and thus is very useful for cell-based regenerative therapy for lacrimal gland-related diseases and cell-based research on the diseases.

公开(公告)号：US20210024896A1

公开(公告)日：2021-01-28

申请号：US16981455

申请日：2019-03-28

Applicant: Osaka University

Inventor： Kohji Nishida ,  Ryuhei Hayashi ,  Toru Okubo ,  Yoichi Honma

IPC: C12N5/074 ,  A61K35/55

Abstract: Provided is a method for producing a stem cell-derived lacrimal gland tissue, the method comprising isolating SSEA4 and CD104 double positive cells from a self-formed ectodermal autonomous multi-zone (SEAM) cell population derived from pluripotent stem cells and three-dimensionally culturing the isolated cells in a medium with epidermal growth factor (EGF) and a ROCK inhibitor to produce a cell population expressing a lacrimal gland-related protein. The present invention provides a lacrimal gland organoid produced from pluripotent stem cells including iPS cells and thus is very useful for cell-based regenerative therapy for lacrimal gland-related diseases and cell-based research on the diseases.